Device/Diagnostics Quarterly Deal Statistics, Q1 2016
Device companies raised 50% more in Q1 2016 than the previous quarter, reaching $1.8 billion and led by debt offerings; diagnostic imaging acquisitions, such as Toshiba Medical Systems, were abundant. Diagnostics financings double in Q1, mostly from venture funding, including strong showing from liquid biopsy companies.
You may also be interested in...
From "smart" snake-like catheters to miniscule-sized devices, a new generation of surgical robots, developed at world-renowned research institutions, aims to explore a new frontier by allowing doctors to target inaccessible areas within the body, and treat conditions with greater precision and better patient outcomes. With the surgical robotics market projected to surpass $10bn by 2021, a growing number of companies are hoping to capture their share in this trending space.
A disclosure from Alere says Abbott did attempt to terminate its agreement to buy the diagnostics company due to an ongoing federal investigation of Alere, but Abbott has reaffirmed its commitment to the deal.
Genetic sequencing company Illumina is betting it can develop the first next-generation sequencing "pan-cancer" screening assay by building a separate company dedicated to the task. The new firm has $100 million in start-up funds and is called Grail.